Neoadjuvant Therapy

"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Descriptor ID	D020360
MeSH Number(s)	E02.186.450
Concept/Terms	Neoadjuvant Therapy Neoadjuvant Therapy Neoadjuvant Therapies Therapies, Neoadjuvant Therapy, Neoadjuvant Neoadjuvant Treatment Neoadjuvant Treatments Treatment, Neoadjuvant Treatments, Neoadjuvant

Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Combined Modality Therapy [E02.186]
Neoadjuvant Therapy [E02.186.450]

Below are MeSH descriptors whose meaning is related to "Neoadjuvant Therapy".

Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.

Bar chart showing 81 publications over 22 distinct years, with a maximum of 9 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2005	0	1	1
2007	1	2	3
2008	0	3	3
2009	0	1	1
2010	1	2	3
2011	2	2	4
2012	1	3	4
2013	3	2	5
2014	1	2	3
2015	0	1	1
2016	3	0	3
2017	1	2	3
2018	1	4	5
2019	1	6	7
2020	1	3	4
2021	6	1	7
2022	3	6	9
2023	0	5	5
2024	4	0	4
2025	2	2	4
2026	1	0	1

Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.

Masanam MK, Bellon JR, Leone JP, Mittendorf EA, King TA, Kantor O. Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2026 Apr; 33(4):3355-3363.

View in: PubMed
Boysen M, Lai SH, Byers S, Widmar M, Loria A, Russell T, Abelson JS, Fleming FJ, Monson JR, Vogel JD. Rectal Cancer Watch-and-Wait Management of Patients With Tumors Within Versus Beyond the Reach of Digital Rectal Examination. Ann Surg Oncol. 2026 Apr; 33(4):2856-2864.

View in: PubMed
Connolly JG, McCullum JC, Munroe C, Gaetani RS, Bliggenstorfer JT, Saraidaridis JT, Kuhnen AH, Marcello PW, Kleiman DA, Abelson JS. Circumferential Rectal Cancer Is a Risk Factor for Stricture Formation and Restaging Uncertainties After Neoadjuvant Therapy. Dis Colon Rectum. 2026 Feb 01; 69(2):181-190.

View in: PubMed
Gaetani RS, Sharma S, Rizvi TZ, Abelson JS. Quality of Life and Functional Outcomes After Watch-and-Wait for Locally Advanced Rectal Cancer: A Meta-analysis. J Surg Res. 2025 11; 315:362-375.

View in: PubMed
Donovan KF, Tomada EP, Carmichael H, Ricardo A, Berger N, Bonaccorso A, Alavi K, Zaghiyan K, Pigazzi A, Sands D, DeBeche-Adams T, Chadi SA, McLemore EC, Marks JH, Maykel JA, Shawki SF, Steele SR, Albert M, Whiteford MH, Wexner SD, Sylla P. Impact of neoadjuvant treatment on functional outcomes after transanal total mesorectal excision (taTME)-a case series. Surg Endosc. 2025 Oct; 39(10):6802-6812.

View in: PubMed
Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, A Choudry H, Holtzman MP, Pingpank JF, O'Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.

View in: PubMed
Bauer PS, Gamboa AC, Otegbeye EE, Chapman WC, Rivard S, Regenbogen S, Hrebinko KA, Holder-Murray J, Wiseman JT, Ejaz A, Edwards-Hollingsworth K, Hawkins AT, Hunt SR, Balch GC, Wise PE. Short-Course TNT Improves Rectal Tumor Downstaging in a Retrospective Study of the US Rectal Cancer Consortium. J Surg Oncol. 2025 Mar; 131(3):498-506.

View in: PubMed
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.

View in: PubMed
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.

View in: PubMed
Zager Y, Horesh N, Abdelmasseh M, Aquina CT, Alfonso BLL, Soliman MK, Albert MR, Monson JRT. The predicting value of post neoadjuvant treatment magnetic resonance imaging: a meta-analysis. Surg Endosc. 2024 11; 38(11):6846-6853.

View in: PubMed

People

Explore

Similar Concepts

Top Journals